Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B™ vaccine

Medical Science Monitor

Volumn 10, Issue 1, 2004, Pages

  Madalińsk, Kazimierz ^a,c   Sylvan, Staffan P E ^b   Hellström, Ulla ^b   Mikołajewicz, Jolanta ^d   Dzierzanowska Fangrat, Katarzyna ^d  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL INSTITUTE OF HYGIENE   (Poland)

^d NONE

Author keywords

Hepatitis B virus; Newborns; Rapid response; Third generation vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; PRES1 PROTEIN ANTIBODY; PRES2 PROTEIN ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VITRONECTIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NEWBORN; SEROCONVERSION;

HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; PROTEIN PRECURSORS;

EID: 0842284171     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Van Damme P: Hepatitis B vaccination programmes in Europe - an update. Vaccine, 2000; 19: 2375-2379
2. Lee CL, Ko YC: Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics, 1997; 99: 351-353
3. Magdzik W: Hepatitis B epidemiology in Poland, Central and Eastern Europe and the Newly Independent States. Vaccine, 2000; 18: S13-S16
4. Mahoney FJ, Kane M: Hepatitis B vaccine. In: Plotkin, SA, Orenstein, WA, (Eds.), Vaccines, 1999; Saunders, London, pp. 158-182
5. West DJ, Calandra GB, Ellis RW: Vaccination of infants and children against hepatitis B. Pediatr Clin N Amer, 1990; 8: 574-578
6. Carman WF, Zanetti AR, Karayianuis P et al: Vaccine-induced escape mutant of hepatitis B virus. Lancet, 1990; 336: 325-329
7. Okamoto H, Yano K, Nozaki Y et al: Mutations within the s gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res, 1992; 32: 264-268
8. Fortuin M, Karthigesu V, Allison L, D'Mello F et al: Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis, 1994; 169: 1374-1376
9. Wilson JN, Nokes DJ, Carman WF: Current status of HBV vaccine escape variants - a mathematical model of their epidemiology. J Viral Hepatitis, 1998; 5 (Suppl 2): 25-30
10. Wilson JN, Nokes DJ, Carman WF: Predictions of the emergence of vaccine-resistant hepatitis B in the Gambia using a mathematical model. Epidemiol Infect, 2000; 124: 295-307
11. Thomas HC: Mechanism of emergence of hepatitis B virus escape variants: approaches to prevention. J Viral Hepatitis, 1998; 5: 31-36
12. Gerlich WH, Heermann KH, Xuanyong L: Functions of hepatitis B surface proteins. Arch Virol, 1992; (Suppl 4): 129-132
13. Neurath AR, Strick N, Kent SBH: Human antibody responses to pre-S-gene coded sequences of the hepatitis-B virus envelope protein. In: Brown F, Chanock RM, Lerner RA. (Eds.), Vaccines 86: New Approaches to Immunization. New York: Cold Spring Harbor Laboratory, 1986; pp. 371-375
14. Neurath AR, Seto B, Strick N: Antibodies to synthetic peptides from the pre-S1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine, 198; 7: 234-236
15. Milich DR: T- and B-cell recognition of hepatitis B viral antigens. Immunology Today, 1998; 9: 380-386
16. Jin Y, Shih W-K, Berkower I: Human T cell response to the surface antigen of hepatitis B virus (HBsAg). J Exp Med, 1988; 168: 293-306
17. Ferrari C, Penna A, Bertoletti A et al: The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest, 1989; 84: 1314-1319
18. Itoh Y, Takai E, Ohnuma H et al: A synthetic peptide vaccine involving the product of the pre-S2 region of hepatitis B virus DNA: Protective efficacy in chimpanzees. Proc Natl Acad Sci, 1986; USA 83, 9174-9178
19. Francois G, Kew M, van Damme P et al: Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine, 2000; 19: 3799-3815
20. Koyanagi T, Nakamuta M, Sakai H et al: Analysis of HBs antigen negative variant of hepatitis B virus: unique substitutions, Glu 129 to Asp and Gly 145 to Ala in the surface antigen gene. Med Sci Monit, 2000; 6: 1165-69
21. Shouval D, Ilan Y, Hourvitz A et al: Immunogenicity of a mammalian cell-derived recombinant hepatitis B vaccine containing pre S and pre S antigens: a preliminary report. In: Nishioka K, Suzuki H, Mishiro S, Oda T (Eds.), Viral Hepatitis and Liver Disease. Springer-Verlag, Tokyo 1994; pp. 543-546
22. Pride MW, Bailey CR, Muchmore E, Thanavala Y: Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products. Vaccine, 1998; 16: 543-550
23. Jones CD, Page M, Bacon A et al: T-cell antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Vaccine, 1999; 17: 2528-2537
24. Young MD, Rosenthal MH, Dickson B et al: A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine. Vaccine, 2000; 19: 3437-3443
25. Tron F, Degos F, Brechot C et al: Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and Pre-S2 sequences. J Infect Dis, 1989; 160: 199-204
26. Yap I, Guan R, Chan SH: Recombinant DNA hepatitis B vaccine containing PreS components of the HBV coat protein: A preliminary study on immunogenicity. Vaccine, 1992; 10: 439-442
27. Raz R, Koren R, Bass D: Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults, Isr Med Assoc J, 2001; 3: 328-332
28. Madalinski K, Zychowicz C, Górnicki J et al: Immunogenicity in children of recombinant hepatitis B vaccine containing S, pre-S2 and pre-S1 antigens. Persistence of antibodies. Polish Journal of Immunology, 1994; 19: 333-340
29. Yerushalmi B, Raz R, Blondheim O et al: Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigen in neonates. Pediatr Infect Dis J, 1997; 16: 587-592
30. Shapira MY, Zeira E, Adler R, Shouval D: Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol, 2001; 34: 123-127
31. Banatvala J, van Damme P, Oehen S: Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine, 2001; 19: 877-875
32. Madalinski K, Sylvan SPE, Hellström U et al: Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine, 2002; 20: 92-97
33. Hellstrom UB, Sylvan SPE: Significance of pre-S2 peptide of hepatitis B virus: Should it be in the vaccine? Prog Med Virol, 1988; 35: 76-106
34. Pillot J, Poynard T, Elias A et al: Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. Vaccine, 1995; 13: 289-294
35. Bucher B, Francioli P, Geudelin B et al: Immunogenicity of a recombinant preS2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. Eur J Clin Microbiol Infect Dis, 1994; 13: 212-217
36. Suzuki H, Iino S, Shiraki K et al: Safety and efficacy of a recombinant yeast-derived preS2+S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine, 1994; 12: 1090-1096
37. Zuckerman JN, Zuckerman AJ, Symington I et al: Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology, 2001; 34: 798-802
38. Suwignyo S, Surya IGP, Mulyanto M et al: The use of a preS2-containing recombinant vaccine for the prevention of maternal transmission of hepatitis B virus in Indonesian neonates, In: Nishioka K, Suzuki H, Mishiro S, Oda T (Eds.), Viral Hepatitis and Liver Disease. Springer-Verlag, Tokyo 1994; pp.536-539
39. Fujisawa Y, Kuroda S, Van Eerd PMCA et al: Protective efficacy of a novel hepatitis B vaccine consisting of M (preS2+S) protein particles (a third-generation vaccine). Vaccine, 1990; 8: 192-198
40. Hellström U, Sylvan SPE, Kuhns M et al: Absence of pre-S2 antibodies in natural hepatitis B virus infection. Lancet, 1986; 2: 889-893
41. Budkowska A, Dubreuil P, Poynard T et al: Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection. Hepatology, 1992; 15: 26-31
42. Chen SH, Howard CR: Properties and stability of the pre-S region of hepatitis B virus. In: Zuckerman AJ (Ed.), Viral Hepatitis and Liver Disease. Alan R Liss Inc, New York 1998; pp. 622-626
43. Fei GZ, Sylvan SPE, Yao GB, Hellstrom UB: IgG antibodies to synthetic peptides mimicking B-cell epitopes within the hepatitis B virus (HBV) envelope preS2 region protein: relation to viremia and liver-disease activity in chronic HBV infection. Centr Eur J Immunol, 1999; 24: 248-256
44. Neurath AR, Kent SHB, Parker K et al: Antibodies to a synthetic peptide from the pre-S 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine, 1986; 4: 35-37
45. Emini EA, Larson V, Eichberg J et al: Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein. J Med Virol, 1989; 28: 7-12
46. Thornton GB, Milich D, Chisari F et al: Immune response in primates to the pre-S2 region of hepatitis-B surface antigen: Identification of a protective determinant. In: Chanock RM, Lerner RA, Brown F, Ginsberg H, (Eds.), Vaccines 87: Modern approaches to new vaccines: prevention of AIDS and other viral, bacterial, and parasitic diseases. Cold Spring Harbor Laboratory, New York 1987; pp. 77-80
47. Halota W, Muszynska M, Pawlowska M: Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Med Sci Monit 2002; 8: CR516-9
48. Chlabicz S, Grzeszczuk A, Lapinski TW: Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-the effect of interferon-alpha therapy. Med Sci Monit, 2002; 8: CR3798-83